AlphaLiquidⓇ100 is a liquid biopsy test designed for patients with advanced solid cancers. Our patented UniqSeqⓇ technology detects minuscule amount of ctDNA (circulating tumor DNA) in the bloodstream for comprehensive genomic analysis.

AlphaLiquidⓇ100 detects the four classes of variations (SNV, INDEL, fusion, and CNV) and the two genomic signatures of immunotherapy (MSI and TMB) in 118 NCCN-recommended genes associated with major cancer types. With this data, IMB Dx can provide information on appropriate therapy options and related on-going clinical trials.

Recommended for：

• Patients who are unable to go through invasive tissue biopsy.
• Patients whose tumor tissue cannot be obtained.
• Patients who have not been tested for a long time, or whose tissue biopsy result is outdated.
• Patients with more than one key mutations detected from recent biopsy.
• Patients who need more than a single gene test for appropriate diagnosis and therapy.

Workflow

Ordering

Sample Collection

Transportation

Analysis Report

Icon reference: Arrow icons created by Creative Stall Premium - Flaticon

118 Gene List

Concordance with Tissue Data

Recommended for patients before anticancer therapy or with cancer in progress.